# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jacqueline du Pré (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML039-SYN
- Date: 2026-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Imogen Thackeray-Osei, MD
- Calendar frame: modern shifted

## What we are working on

- For three weeks the fingers of both hands have been numb and tingling, worse on the left; she cannot feel the strings properly, loses her place on the fingerboard and has dropped her bow twice; an electric feeling runs down her back when she bends her head; tired by mid-afternoon for months **S**
- A similar month of tingling in her fingers 18 months ago was put down to overwork and stress, and settled **S**
- She wants to know what is wrong, and whether she will be able to play again **S**

## Your goals

- MRI of the brain and spine within one week and a neurology diagnosis within three weeks. Target: 2026-03-23. Recorded outcome: MRI in three days, lumbar puncture in a week, diagnosis and consultation at two weeks. **S**
- High-efficacy disease-modifying therapy started within six weeks of diagnosis, after screening and vaccinations. Target: 2026-04-27. Recorded outcome: Ocrelizumab started three weeks after the diagnosis; PCV20, recombinant zoster and hepatitis B vaccines given first. **S**
- Nine-hole peg times back to within 10 percent of normal in both hands, and full practice resumed. Target: 2026-07-13. Recorded outcome: 19.0 seconds right and 20.5 seconds left at three months; practicing three hours a day. **S**
- No evidence of disease activity at six months (no relapse, no new or enhancing MRI lesion, no disability progression). Target: 2026-10-12. Recorded outcome: No relapse; re-baseline MRI with no new or enhancing lesions; examination stable. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more. Target: 2026-07-13. Recorded outcome: 34 ng/mL after 16 weeks of cholecalciferol. **S**
- PHQ-9 below 10 throughout. Target: 2026-10-12. Recorded outcome: PHQ-9 between 3 and 7. **S**

## What we agreed to do

- Neurology (multiple sclerosis) consultation within two weeks to review the MRI with her and make a diagnosis and plan. Guideline: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022) **S**
- Urgent work-up of a sensory syndrome of both hands with Lhermitte's sign: MRI of the brain and cervical and thoracic spine with gadolinium within a week; blood count, chemistry, vitamin B12 and TSH; lumbar puncture for oligoclonal bands if the MRI is suggestive; return at once for weakness, unsteadiness, loss of bladder control or loss of vision. Guideline: Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162-173 (PMID 29275977) (2017); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021) **S**
- Relapse treatment: methylprednisolone 1 g intravenously daily for three days for a relapse that limits her hand function, after excluding infection; occupational therapy for hand function and energy management. Guideline: Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Multiple sclerosis in adults: management (NICE guideline NG220) (2022) **S**
- Early high-efficacy disease-modifying therapy with ocrelizumab: 300 mg intravenously on days 1 and 15, then 600 mg every six months, with premedication; chosen over natalizumab because the JCV antibody is positive and over ofatumumab at her preference for twice-yearly infusions; before the first dose, hepatitis B screening, varicella and measles immunity, immunoglobulins, a pregnancy test, and inactivated vaccines at least two weeks ahead; contraception during treatment. Guideline: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Hauser SL, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017;376(3):221-234 (PMID 28002679) (2017); Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019) **S**
- Vitamin D: cholecalciferol 4000 units daily to correct deficiency, with a level after three months; not as a treatment for multiple sclerosis. Guideline: Multiple sclerosis in adults: management (NICE guideline NG220) (2022) **S**
- Monitoring on ocrelizumab: re-baseline MRI of the brain three to six months after starting, then yearly; blood count and immunoglobulins before each dose; infection and pseudo-relapse teaching; pregnancy planning, with conception timed after a dose. Guideline: Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018); Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018); Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021) **S**
- Fatigue, mood and work: screening for depression and sleep problems at each visit, plain explanations with written information, and a plan built around her practice, performing and teaching; she decides who is told and who receives each note. Guideline: Multiple sclerosis in adults: management (NICE guideline NG220) (2022); Depression and Suicide Risk in Adults: Screening (2023) **S**

## Follow-up

- 2026-03-09: Three weeks of numbness and clumsiness in the fingers of both hands, with Lhermitte's sign and fatigue, in a professional cellist of 28: examination, blood tests, and urgent MRI of the brain and spine **S**
- 2026-03-23: Diagnosis of relapsing-remitting multiple sclerosis: neurology consultation, treatment of the relapse, choice of high-efficacy disease-modifying therapy, and vaccinations before B-cell therapy **S**
- 2026-04-27: Second half-dose of the first ocrelizumab course: recovery of hand function, infusion reactions, vaccination, practice and work **S**
- 2026-07-13: Three months on ocrelizumab: re-baseline MRI, B-cell depletion, fatigue, vitamin D and hand function **S**
- 2026-09-14: Periodic adult preventive visit on B-cell therapy **S**
- 2026-10-12: Six months: first 600 mg dose of ocrelizumab, no evidence of disease activity, immunoglobulins, vaccination response, pregnancy planning and her return to performing **S**

This teaching document does not replace care from a qualified clinician.
